Article Text

Download PDFPDF
Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy
  1. Y. Pan* and
  2. M.-S. Kao
  1. * Department of Neurology, Saint Louis University Hospital, St. Louis, Missouri
  2. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, Saint Louis University, St. Louis, Missouri
  1. Address correspondence and reprint requests to: Yi Pan, MD, PhD, Department of Neurology, Saint Louis University Hospital, 3635 Vista Avenue, St. Louis, MO 63110, USA. Email: pany{at}


Paclitaxel combined with carboplatin is currently accepted as the first-line treatment for ovarian carcinoma, frequently associated with neuropathy. Due to its frequent association with neuropathy, combination of docetaxel and carboplatin has been suggested as an alternative. A 47-year-old woman developed paresthesia after the first cycle of paclitaxel/carboplatin for ovarian cancer. Her nerve conduction study (NCS) showed only sural neuropathy after completion of six cycles, which returned to normal in 6 months. She had fewer neuropathy symptoms when treatment was changed to docetaxel/carboplatin for recurrent cancer. NCS revealed generalized sensory neuropathy following docetaxel/carboplatin treatment, which normalized after 12 months. Our observation indicated that there is a disparity between clinical symptoms and electrophysiologic examination in taxane-induced neuropathy. Although docetaxel was tolerated well by the patient, evidence of generalized sensory neuropathy was present in NCS

  • carboplatin
  • docetaxel
  • neuropathy
  • nerve conduction study
  • paclitaxel

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.